Pepscope is an innovative biotechnology company that develops and offers protein activity phosphoproteomics platforms to increase the success rate of novel medicines and bring them to patients faster.
Our proprietary platform, QuantaKinome™, allows the direct quantification of endogenous signal transduction protein activities in human cells and tissues. QuantaKinome™ offers unique insights into the Mechanism Of Action (MOA) and related effects of compounds on cell signaling pathways. Combined with advanced bioinformatics, thorough data analyses, and transparent reporting, Pepscope delivers actionable information about compound effects.
Pepscopes’ quantitative, targeted mass spectrometry technology is an excellent fit for MOA and biomarker analyses in a range of human cell samples. It opens the door to a better understanding of the in situ effects of drugs. QuantaKinome™ also provides crucial information to correlate early signaling to long-term compound effects. As a result, our platforms are suitable for reverse translation of compound safety data into mechanistic insights.
The Pepscope team consists of highly skilled scientists and experienced entrepreneurs with ample experience in innovative technology development for protein analyses. We take pride in supporting our (bio-)pharmaceutical customers with unique compound insights, passion, and a firm commitment to adhere to the highest quality standards.
Pepscope is based in the Netherlands, with offices and laboratories in Utrecht and Wageningen.
The Pepscope Team
CEO & Co-Founder
Anna is a pragmatic leader and team player with longstanding experience in proteomics. She joined Pepscope in 2018 as Scientific Lead in mass spectrometry, bringing over eight years of experience in academic and industrial R&D, including Nerviano Medical Sciences. In 2018, Anna took the initiative for a strategic partnership between Pepscope and Utrecht University, resulting in the adoption of QuantaKinome technology. She has led the Pepscope team since 2019, culminating in accepting a position as CEO in 2020. This appointment coincided with the completion of a successful investment of €4.3 million, in which she played a crucial role. Anna obtained her Ph.D. at the Utrecht University in the Biomolecular Mass Spectrometry & Proteomics group, has a cum laude M.Sc. in Chemistry from the University of Bologna, and a degree in Cancer Pharmacology from the University of Milan.
Head of Services
Giulia De Sabbata
Giulia joined Pepscope in 2020 as scientist experienced in molecular biology and proteomics technologies. She obtained her Ph.D. in Life and Molecular Sciences at the International Centre for Genetic Engineering and Biotechnology (ICGEB) in Italy. During her studies, she focused on developing novel proteomics workflows using immunoprecipitation coupled to mass spectrometry to study protein-protein interaction pathways and their perturbation in diseases. Previously, Giulia took part in a multi-laboratory collaboration project with Selecta Biosciences and Genethon where she contributed to pre-clinical development of a new AAV-based gene therapy for treatment of OTC deficiency.
Junior Research Technician
Jaylen joined Pepscope in 2021 as a Junior Research Technician. He obtained his bachelor in Biological and Medical Laboratory Research, at the University of Engineering and Applied Science in Rotterdam. During his study, he performed an internship at Bioceros, department of Analytical Development in Utrecht, where he gained experience in proteomics method development. After finishing his study, he worked as an Analyst at HAL Allergy, Quality Control department in Leiden. Here he gained experience in working under GMP quality guidelines and has shown a strong passion for automation.
Head of Technology
Erik de Graaf
Erik joined Pepscope in 2019 as senior scientist experienced in proteomics techniques, clinical lab automation and molecular characterization of human cancer. Erik obtained his Ph.D. in the Biomolecular Mass Spectrometry & Proteomics group at Utrecht University where he mastered advanced and state-of-the-art MS-based proteomics techniques to study protein phosphorylation in aging and cancer. Erik worked for 2 years at the Fondazione Pisana per la Scienza in Italy where he led the development and automation of MS assays for proteomics analysis in clinical tissues. Before joining Pepscope, Erik worked 3 years at Sanquin Research where he applied his knowledge to investigate human antibodies.
Sidrah joined Pepscope in 2017 with experience in protein characterization and quality control. She is currently responsible for overseeing the daily laboratory operations at Pepscope. She studied Biology and Medical Laboratory Research, followed by a Master’s degree in Biomedical Sciences at Leiden University in 2014. Sidrah worked at the quality control department at Jansen Biologics, followed by HAL Allergy in 2016, where she focused on method development for protein quantification and protein characterization.
Ksenia joined Pepscope in 2021 as a bioinformatician. She studied chemistry and bioinformatics at the University of Chemistry and Technology in Prague and obtained her Master's degree in 2020. Ksenia worked as a bioinformatics scientist for a company providing cloud-based solutions for bioinformatics research. Previously, Ksenia worked as a bioinformatician at SOTIO Biotech as a part of a multidisciplinary team of biologists. Ksenia was responsible for setting up the NGS pipelines from scratch, performing computational analyses in the context of immuno-oncology from raw data to pathway analysis, and visualizing the results.
Head of Biology
Nynke joined Pepscope in 2018 as a biological scientist with expertise in kinase phosphorylation in the field of immunology and transplantation. Nynke studied Biopharmaceutical Sciences at Leiden University and obtained her master’s degree in 2013. In 2018, she completed her doctoral training within the Rotterdam Transplant Group of the Erasmus Medical Center. During her Ph.D. project, she investigated new pharmacodynamic assays for monitoring signaling pathways after transplantation, assessing the phosphorylation status of protein kinases in immune cells.
Junior Lab Technician
Niek joined Pepscope in 2021 as a Junior Lab Technician. Niek obtained his Bachelor of Science in Biology and Medical Laboratory Research at the institute for Engineering and Applied Science, Hogeschool Rotterdam. He completed his 4th year internship at Erasmus MC, department Neurosurgery in the group of Jeroen de Vrij, where he gained experience in the fields of cell culturing, high-content screening fluorescent microscopy, oncolytic viruses, and exosomes. Moreover, he worked as an evening/weekend technician at ViroClinics-DDL, where he tested samples for COVID-19. Niek has a strong commitment to cancer research and a passion for proteomics.
Annejet Morris – Gülcher
Annejet joined Pepscope in 2021 with experience in setting up office administrative processes. After working more than ten years in several industries across South Africa and Europe, Annejet joined Sue Ryder as Online Shop Team Lead in 2014. There she was responsible for setting up procedures, improving customer service, and increasing the overall feedback scores on the selling platforms. She completed an ILM-approved Management Development program in 2016. In 2019, Annejet joined Basecone, an IT scale-up in the Netherlands, where she was responsible for office management and an office refurbishment project.
Board and Advisors
Chairman of the Board & Co-Founder
Jos is a biotech entrepreneur with over 20 years of executive level bio-business experience in companies including Mimetas, Pepscan, SkylineDx, Kreatech Diagnostics (now part of Leica Biosystems ) and Westburg. He is a co-founder of Pepscope and CEO and co-founder of Mimetas. As a scientist, he studied vertebrate embryonal axis formation and brain development at the Hubrecht Institute (Utrecht, NL) and King’s College (London, UK). He has published over 50 scientific papers and patents. Jos holds a cum laude master’s degree in business marketing, a master’s degree in biology and a Ph.D. in developmental biology.
Board Member and Co-Founder
Hans studied Applied Physics at Delft University of Technology, graduating (Ir.) in 1982. After working for Philips, ASMI NV and European Silicon Structures Ltd, a high tech semiconductor company, he started his first business, CPS Europe, developing electronic products in 1993. He is a co-founder of Pepscope, founder of Omniradar and Optics11 and holds several patents.
Maarten is associate professor at the Department of Pharmaceutical Sciences of the Utrecht University and head of the proteomics facility at The Netherlands Cancer Institute (NKI). His research focuses on the development and implementation of innovative mass spectrometric methods for the characterization of proteins, protein complexes and their post-translational modifications in relation to their biological function in health and disease. He has published over 90 scientific papers. Maarten received a prestigious VIDI grant in 2013, is a partner in large research consortia such as X-Omics.nl and Epic-XS and is currently the treasurer of the Dutch Society for Mass Spectrometry (NVMS), and the International Mass Spectrometry Foundation (IMSF).